Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests simple strategies to keep HIV patients on track

NCT ID NCT05040841

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests different ways to help people with HIV take their medication regularly. Researchers will enroll 534 people starting HIV treatment in Cape Town. They will use a device to track pill-taking and try different outreach methods, like calls or texts, to support adherence. The goal is to see which strategies help more people achieve undetectable virus levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioural intervention (outreach calls, texts, and adherence support)
What this could lead to
If successful, this could show which simple, low-cost strategies best help people stay on HIV treatment and keep the virus under control.
What could go wrong
This is a behavioral study, not a drug trial, so it won't cure HIV. Results may vary by clinic and may not apply to all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

534 people

The number who actually took part.

Started

Mar 2022

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Main study: * Adults (≥18 years) and adolescents 16-17 years. * HIV-positive and attending a local City of Cape Town (COCT) clinic to commence ART. * Able to provide full informed consent, with a written signature. For those who are illiterate, a witness will be present throughout the process and will sign the form, while the participant will add their right thumb print. For those who are aged 16-17 years, informed written assent will be obtained, and the adolescent must have a parent or guardian who can provide full informed consent (see \*\*below for how parent/guardian is defined for this purpose). * Access to a working cellphone and willingness to receive study-related messaging on that phone. * Willingness to comply with study procedures, including providing regular updates of contact details /locator information, and use a EAM device for the duration of participation. Other Inclusion Criteria: Aim 1: In-depth interviews (IDIs) with subset of trial subjects at baseline and months 12 and 24. * Participation in the main trial. * Self-reported prior experience with substance use, depression, gender inequity, stigma, or transport/clinic issues. Aim 2: Questionnaires and IDIs with staff members at study clinics (three total clinics). * Adults (≥18 years) * Staff at study clinics, providing HIV care and/or treatment. Aim 2: Focus group discussion (FGD) with City of Cape Town officials. * Adults (≥18 years) * Staff at City of Cape Town. Exclusion Criteria - Main study: * Clinical conditions as assessed by the COCT clinic clinicians at first visit e.g. renal disease, which preclude the use of a single tablet regimen (with the exception of those on tuberculosis (TB) treatment who are required to take an extra dose of dolutegravir daily). * Planning to leave Cape Town permanently within the next 24 months. * Being perinatally infected with HIV. Being infected from birth typically means a set of experiences and complications at a young age that require unique and special attention. * If an adolescent, taking their ART medication as a syrup, as they are required to use the electronic adherence monitor (Wisepill device), which is only suitable for tablets. Other Inclusion Criteria: Aim 1: IDIs with trial subjects. • None. Aim 2: Questionnaires and IDIs with staff members at clinics. • None. Aim 2: FGD with City of Cape Town officials. • None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, medication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mzamomhle

    Cape Town, Western Cape, South Africa

  • Phumlani

    Cape Town, Western Cape, South Africa

  • Weltevreden Valley

    Cape Town, Western Cape, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.